AstraZeneca/Daiichi Make Their Case For Dato-DXd In Non-Squamous Lung Cancer

Early-Stage PD-L1/Chemo Combo Data Also Reported

 
• By Mandy Jackson
  
Futuristic medical concept with blue human lungs
AstraZeneca used a proprietary AI-based model to analyze TROP2 expression • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D